<?xml version='1.0' encoding='utf-8'?>
<document id="11791889"><sentence text="Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo."><entity charOffset="50-62" id="DDI-PubMed.11791889.s1.e0" text="ketoconazole" /><entity charOffset="68-77" id="DDI-PubMed.11791889.s1.e1" text="clozapine" /><pair ddi="false" e1="DDI-PubMed.11791889.s1.e0" e2="DDI-PubMed.11791889.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s1.e0" e2="DDI-PubMed.11791889.s1.e1" /></sentence><sentence text="The drug-food and drug-drug interaction between grapefruit juice (GFJ) and ketoconazole (KETO) was evaluated in schizophrenic patients given a single dose of clozapine (CLZ)"><entity charOffset="75-87" id="DDI-PubMed.11791889.s2.e0" text="ketoconazole" /><entity charOffset="89-93" id="DDI-PubMed.11791889.s2.e1" text="KETO" /><entity charOffset="158-167" id="DDI-PubMed.11791889.s2.e2" text="clozapine" /><entity charOffset="169-172" id="DDI-PubMed.11791889.s2.e3" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.11791889.s2.e0" e2="DDI-PubMed.11791889.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s2.e0" e2="DDI-PubMed.11791889.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s2.e0" e2="DDI-PubMed.11791889.s2.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s2.e0" e2="DDI-PubMed.11791889.s2.e3" /><pair ddi="false" e1="DDI-PubMed.11791889.s2.e1" e2="DDI-PubMed.11791889.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s2.e1" e2="DDI-PubMed.11791889.s2.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s2.e1" e2="DDI-PubMed.11791889.s2.e3" /><pair ddi="false" e1="DDI-PubMed.11791889.s2.e2" e2="DDI-PubMed.11791889.s2.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s2.e2" e2="DDI-PubMed.11791889.s2.e3" /></sentence><sentence text=" CLZ is metabolized primarily by CYP isozymes 3A4 and 1A2 to two principal metabolites, desmethylclozapine (DCLZ) and clozapine N-oxide (CNO)"><entity charOffset="88-106" id="DDI-PubMed.11791889.s3.e0" text="desmethylclozapine" /><entity charOffset="108-112" id="DDI-PubMed.11791889.s3.e1" text="DCLZ" /><entity charOffset="118-135" id="DDI-PubMed.11791889.s3.e2" text="clozapine N-oxide" /><entity charOffset="137-140" id="DDI-PubMed.11791889.s3.e3" text="CNO" /><entity charOffset="1-3" id="DDI-PubMed.11791889.s3.e4" text="CLZ" /><entity charOffset="109-111" id="DDI-PubMed.11791889.s3.e5" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e4" e2="DDI-PubMed.11791889.s3.e4" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e4" e2="DDI-PubMed.11791889.s3.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e4" e2="DDI-PubMed.11791889.s3.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e4" e2="DDI-PubMed.11791889.s3.e5" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e4" e2="DDI-PubMed.11791889.s3.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e4" e2="DDI-PubMed.11791889.s3.e3" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e0" e2="DDI-PubMed.11791889.s3.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e0" e2="DDI-PubMed.11791889.s3.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e0" e2="DDI-PubMed.11791889.s3.e5" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e0" e2="DDI-PubMed.11791889.s3.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e0" e2="DDI-PubMed.11791889.s3.e3" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e1" e2="DDI-PubMed.11791889.s3.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e1" e2="DDI-PubMed.11791889.s3.e5" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e1" e2="DDI-PubMed.11791889.s3.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e1" e2="DDI-PubMed.11791889.s3.e3" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e5" e2="DDI-PubMed.11791889.s3.e5" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e5" e2="DDI-PubMed.11791889.s3.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e5" e2="DDI-PubMed.11791889.s3.e3" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e2" e2="DDI-PubMed.11791889.s3.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s3.e2" e2="DDI-PubMed.11791889.s3.e3" /></sentence><sentence text=" GFJ and KETO are well known potent CYP 3A4 inhibitors in the gastrointestinal tract and hepatic isozymes, respectively"><entity charOffset="9-11" id="DDI-PubMed.11791889.s4.e0" text="KETO" /></sentence><sentence text=" Twenty-one schizophrenic patients participated in the co-administration of CLZ 50 mg and GFJ"><entity charOffset="76-79" id="DDI-PubMed.11791889.s5.e0" text="CLZ" /></sentence><sentence text=" After a one-week washout, five patients were given double the GFJ (HGFJ) dose for 7 consecutive days" /><sentence text=" In another group of five patients, ketoconazole (KETO) 400 mg was given for 7 consecutive days"><entity charOffset="36-48" id="DDI-PubMed.11791889.s7.e0" text="ketoconazole" /><entity charOffset="50-54" id="DDI-PubMed.11791889.s7.e1" text="KETO" /><pair ddi="false" e1="DDI-PubMed.11791889.s7.e0" e2="DDI-PubMed.11791889.s7.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s7.e0" e2="DDI-PubMed.11791889.s7.e1" /></sentence><sentence text=" At the end of the 7-day period for both groups, CLZ was coadministered with the HGFJ and KETO groups"><entity charOffset="90-94" id="DDI-PubMed.11791889.s8.e0" text="KETO" /><entity charOffset="49-52" id="DDI-PubMed.11791889.s8.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.11791889.s8.e1" e2="DDI-PubMed.11791889.s8.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s8.e1" e2="DDI-PubMed.11791889.s8.e0" /></sentence><sentence text=" CLZ, DCLZ and CNO were assayed by HPLC"><entity charOffset="6-10" id="DDI-PubMed.11791889.s9.e0" text="DCLZ" /><entity charOffset="1-4" id="DDI-PubMed.11791889.s9.e1" text="CLZ" /><entity charOffset="7-10" id="DDI-PubMed.11791889.s9.e2" text="CLZ" /><entity charOffset="15-18" id="DDI-PubMed.11791889.s9.e3" text="CNO" /><pair ddi="false" e1="DDI-PubMed.11791889.s9.e1" e2="DDI-PubMed.11791889.s9.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s9.e1" e2="DDI-PubMed.11791889.s9.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s9.e1" e2="DDI-PubMed.11791889.s9.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s9.e1" e2="DDI-PubMed.11791889.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11791889.s9.e0" e2="DDI-PubMed.11791889.s9.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s9.e0" e2="DDI-PubMed.11791889.s9.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s9.e0" e2="DDI-PubMed.11791889.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11791889.s9.e2" e2="DDI-PubMed.11791889.s9.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s9.e2" e2="DDI-PubMed.11791889.s9.e3" /></sentence><sentence text=" GFJ, HGJF and ketoconazole failed to significantly change CLZ disposition"><entity charOffset="15-27" id="DDI-PubMed.11791889.s10.e0" text="ketoconazole" /><entity charOffset="59-70" id="DDI-PubMed.11791889.s10.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.11791889.s10.e0" e2="DDI-PubMed.11791889.s10.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s10.e0" e2="DDI-PubMed.11791889.s10.e1" /></sentence><sentence text=" Metabolites DCLZ and CNO concentrations remained unchanged during the study"><entity charOffset="14-16" id="DDI-PubMed.11791889.s11.e0" text="CLZ" /><entity charOffset="13-15" id="DDI-PubMed.11791889.s11.e1" text="DCLZ" /><entity charOffset="22-24" id="DDI-PubMed.11791889.s11.e2" text="CNO" /><pair ddi="false" e1="DDI-PubMed.11791889.s11.e1" e2="DDI-PubMed.11791889.s11.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s11.e1" e2="DDI-PubMed.11791889.s11.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s11.e1" e2="DDI-PubMed.11791889.s11.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s11.e0" e2="DDI-PubMed.11791889.s11.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s11.e0" e2="DDI-PubMed.11791889.s11.e2" /></sentence><sentence text=" The only exception was decreased Cmax in DCLZ and CNO concentrations"><entity charOffset="43-45" id="DDI-PubMed.11791889.s12.e0" text="CLZ" /><entity charOffset="42-44" id="DDI-PubMed.11791889.s12.e1" text="DCLZ" /><entity charOffset="51-53" id="DDI-PubMed.11791889.s12.e2" text="CNO" /><pair ddi="false" e1="DDI-PubMed.11791889.s12.e1" e2="DDI-PubMed.11791889.s12.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s12.e1" e2="DDI-PubMed.11791889.s12.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s12.e1" e2="DDI-PubMed.11791889.s12.e2" /><pair ddi="false" e1="DDI-PubMed.11791889.s12.e0" e2="DDI-PubMed.11791889.s12.e0" /><pair ddi="false" e1="DDI-PubMed.11791889.s12.e0" e2="DDI-PubMed.11791889.s12.e2" /></sentence><sentence text=" These results indicate that CYP 3A4 inhibition may not be clinically significant compared to CYP 1A2, as previous studies show a dramatic increase in CLZ plasma concentrations with fluvoxamine (CYP 1A2 inhibitor)"><entity charOffset="182-193" id="DDI-PubMed.11791889.s13.e0" text="fluvoxamine" /><entity charOffset="151-161" id="DDI-PubMed.11791889.s13.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.11791889.s13.e1" e2="DDI-PubMed.11791889.s13.e1" /><pair ddi="false" e1="DDI-PubMed.11791889.s13.e1" e2="DDI-PubMed.11791889.s13.e0" /></sentence><sentence text=" The reasons for the lack of drug-food and drug-drug interactions with CLZ and CYP 3A4 inhibitors can be explained by the higher Ki values for gastrointestinal and hepatic CYP 3A4 isozymes"><entity charOffset="71-73" id="DDI-PubMed.11791889.s14.e0" text="CLZ" /></sentence><sentence text="" /></document>